Dandruff, Seborrheic Dermatitis and Hair Loss: What Is Actually Linked

Over six months, medicated shampoo cut hair shedding by 17.3% and increased shaft diameter by 5.4%. Hair density did not move at all. Both of those results are in the same study, and which one you quote decides whether you sound optimistic or straight with people.

Dandruff and hair loss turn up together constantly, and the internet has settled on a simple story: the flaking causes inflammation, the inflammation kills follicles, so treat the flaking and keep your hair. The real picture is more interesting and less flattering to that story. The association is genuine. The mechanism is well characterised. And the evidence that fixing your scalp regrows hair is much thinner than twenty years of shampoo marketing has led people to believe.

The association is real, and its shape matters

A 2025 cross-sectional study looked at 311 patients with androgenetic alopecia. Seborrheic dermatitis was present in 131 of them, or 42.1%. As androgenetic alopecia got more severe, seborrheic dermatitis severity scores rose significantly, with a p value below 0.001.^[1]

Now read the second half of that result, which most coverage skips. The rise in seborrheic dermatitis prevalence across alopecia severity groups was not statistically significant, at p equal to 0.28. Only the severity gradient reached significance.

Bidirectional is the word the authors use, and it’s the right one. A scalp losing hair is a scalp with more exposed skin, altered sebum flow and a changed microenvironment. Seborrheic dermatitis could be a driver, a consequence, or both.

What dandruff is, which is not what most people think

The intuitive model is fungus: too much Malassezia, hence flaking, hence kill the fungus. That model is wrong in an instructive way.

The definitive statement comes from a 2005 paper that resolved the field’s central puzzle: there is a lack of correlation between Malassezia number and the presence and severity of dandruff.^[2] Counting the yeast doesn’t predict who flakes.

What does predict it is a three-way convergence. Malassezia must be present. It feeds on sebaceous triglycerides and liberates free fatty acids, oleic acid in particular. And the individual must be sensitive to those fatty acids. Remove any one leg and there’s no dandruff. Two people with identical fungal loads can have completely different scalps because their sensitivity differs.

The way I picture it: the fungus is a tenant, the sebum is the rent it gets paid in, and the flaking is your own reaction to the noise. Evict the tenant and the noise stops. But two neighbours with identical tenants can be bothered to completely different degrees, and that difference is you, not the tenant.

One thing worth flagging: all six authors of that paper worked for Procter and Gamble, and it closes by recommending zinc pyrithione, which is their active. The mechanism is well supported elsewhere. The recommendation at the end is marketing.

The inflammation bridge, and the finding that complicates it

Here’s where the “dandruff causes hair loss” story gets its plausibility. In androgenetic alopecia, there is inflammation around the follicles, and it sits in a specific place.

A 1992 ultrastructural study found that control biopsies from non-balding scalp were devoid of follicular inflammation, while transitional zones consistently showed activated T-cell infiltrates around the lower follicular infundibula, reaching as far as the bulge, where the follicle’s stem cells live.^[3] The infundibulum is the upper part of the follicle canal. It is exactly where Malassezia and its fatty acid metabolites are. That anatomical overlap is the bridge between scalp surface and follicle, and it’s a good argument.

The field named the phenomenon microinflammation.^[4] Then in 2026 somebody compared the histology directly. Across 56 transverse scalp biopsies, 21 from androgenetic alopecia and 35 from seborrheic dermatitis, perifollicular inflammation and fibrosis were common in both conditions and non-specific to either.^[5]

That’s awkward for the simple version. The inflammation held up as androgenetic alopecia’s mechanism is also routine in a condition that does not cause pattern baldness. It looks more like a common final pathway than a specific driver. And the 1992 study was four patients with three controls, which is a mechanistic case series, not evidence of how often any of this happens.

So does treating dandruff grow hair

Partly. And the answer depends entirely on which endpoint you look at.

The strongest evidence comes from a randomised trial of 200 men comparing 5% minoxidil, 1% pyrithione zinc shampoo, both, and placebo. The hair count increase from the zinc shampoo alone was slightly less than half that of minoxidil, significant against placebo from week 9 and sustained through week 26.^[6]

Half of minoxidil, from a shampoo. That is an impressive result and it is the load-bearing citation for the whole idea that scalp treatment does something real. Two caveats keep it in proportion. The trial was investigator-blinded rather than double-blind, and the comparison is structurally lopsided, since a shampoo used at wash time is competing against a twice-daily leave-on solution. Also worth noting: combining the two gave no advantage over minoxidil alone.

Then there is the study that shows the ceiling, and it comes from the same research group that generated the original optimistic finding. Across 150 men over six months on three different antidandruff actives, hair shedding fell and shaft diameter rose. Hair density was unchanged.^[7]

How strong is the ketoconazole evidence, really

Thinner than you’d guess from how confidently it gets recommended.

A 2020 systematic review screened 47 papers on topical ketoconazole for androgenetic alopecia. Seven qualified: two animal studies and five human studies totalling 318 participants. Exactly one reported a significant increase in pilary index.^[8] The studies were too heterogeneous to pool, so there is no meta-analytic effect size, and the review ends by calling for randomised controlled trials.

Which shampoo, then

For dandruff itself, the comparative data is decent. Ketoconazole 2% beat zinc pyrithione 1% at week 4, with 73% versus 67% improvement in total dandruff severity, in 331 randomised subjects.^[10] Six percentage points, in an open-label trial with asymmetric dosing between the arms.

Against selenium sulfide 2.5%, ketoconazole was statistically superior at day 8 only, and both beat placebo throughout. All nine adverse events in the treatment phase occurred in the selenium sulfide group.^[11]

Ciclopirox 1% is worth knowing about for a different reason. In 499 randomised US patients it produced effective treatment in 26.0% versus 12.9% on vehicle, an odds ratio of 2.383.^[12]

So what do you do with this

Treat the dandruff. Not because it’ll regrow your hair, but because an itchy, flaking, inflamed scalp is worth fixing on its own terms, the treatment is cheap and safe, and the evidence that it reduces shedding and thickens the shaft is reasonable even where the density evidence is not.

If the scalp is inflamed, painful or not responding to over-the-counter shampoo within a few weeks, see a dermatologist. Seborrheic dermatitis has prescription options and scalp psoriasis looks similar and is treated differently.

Rotate actives rather than sticking to one. Ketoconazole 2% has the best head-to-head data for dandruff clearance, but selenium sulfide and ciclopirox both beat vehicle, and the differences between them are small enough that tolerability and what your scalp responds to should decide. Leave it on for a few minutes before rinsing, since contact time is how a shampoo delivers an active at all.

And set the expectation correctly, because this is where people go wrong. If your hair loss is androgenetic, dandruff is a passenger, not the driver. Treating it will make your scalp comfortable and may reduce how much comes out in the shower. It won’t stop miniaturisation, because miniaturisation is androgen-driven and no shampoo addresses that. If you want the density number to move, that requires a treatment aimed at the actual mechanism. I have covered what the evidence supports for that in my piece on ketoconazole 1% versus 2% and in the combination therapy guide.

The summary is that this is a real association with a well-understood mechanism and a modest, well-documented effect on two endpoints out of three. That isn’t nothing. It’s also not the missing piece anyone is hoping it will be.